Medivolve Inc
MEDVD
Other OTC0.11
USD
- -
- -
Medivolve Inc
MEDVD
(Other OTC)
Recent
price
0.11
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medivolve Inc. (NEO: MEDV; OTC: MEDVF; FRA: 4NC) operates as a healthcare technology company focused on reinventing the U.S. healthcare system through a bespoke telehealth platform, clinical diagnostic network, and data-driven artificial intelligence framework to enhance patient care; it provides diagnostic testing including COVID-19 rapid antibody blood tests, RT-PCR tests, and antigen tests, vaccinations, point-of-care services via a network of retail collection sites, immunity scoring solutions, telehealth video conferencing, appointment scheduling and management tools, provider and patient interfacing, credit card payment processing, and HIPAA-compliant API integrations for physician consultations, clinical diagnostics, and prescription services. The company targets patients and healthcare providers in the fragmented U.S. market with disruptive technologies to identify, treat, and prevent medical issues, offering holistic health views through streamlined data-driven networks; it operates retail patient-care facilities through subsidiaries in California, with pharmaceutical distribution access via pharmacy acquisitions such as the agreement for outstanding shares of CalVax licensed Marbella Pharmacy providing immediate CalVax licensing throughout California and near-term COVID-19 capabilities. Founded in 2005 and headquartered in Toronto, Ontario, at 65 Queen Street West Suite 800, Medivolve maintains operations across North America including sites in Las Vegas, Nevada; recent developments include a January 2024 master services agreement with Builder.ai for telehealth platform development substantially completed within seven months, management changes with CEO David Preiner departing in August 2024, cease trade order issuance in September 2024 due to filing defaults, and a strategic pivot toward a profitable SaaS-based health-tech model emphasizing data-driven clinical diagnostics, physician recommendations, and prescriptions.
Medivolve Announces Management Changes
Medivolve announces telehealth platform development contract; management and director changes
Medivolve establishes a management services organization in Puerto Rico
Medivolve closes previously announced secured convertible note financing for aggregate gross proceeds of $1.2M